Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL

Phase 1 Completed 72 enrolled Boehringer Ingelheim

RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate safety, tolerability, pharmacokinetics including dose proportionality, and pharmacodynamics of BI 187004 CL within a predefined dose range

Timeline

Start: 2012-04
Primary completion: 2012-10
Completion: 2012-10

Publications

Bianzano S, Heise T, Jungnik A, Schepers C, Scholch C, Grafe-Mody U. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity. Clin Diabetes Endocrinol. 2021 Aug 15;7(1):16. doi: 10.1186/s40842-021-00130-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BI 187004	Small molecule	5 mg	Oral
Subject	BI 187004	Small molecule	10 mg	Oral
Subject	BI 187004	Small molecule	160 mg	Oral
Subject	BI 187004	Small molecule	360 mg	Oral

Indications

No indication recorded.